At Aminoverse I support the development and commercialisation of bioanalytical enzyme assay solutions for biopharmaceutical applications. My career has consistently sat at the intersection of academic rigour and industrial application: a PhD in Enzyme Biotechnology from the University of Reading, UK focused on the structural biology and engineering of industrial proteases, followed by a Post-Doctoral position bridging the University of Reading and Clasado Biosciences on the bioengineering of glycoside hydrolases for prebiotic ingredient production. My technical foundation spans structural biology (X-ray crystallography), molecular biology, protein engineering and advanced bioanalytics (HPLC, HPAEC-PAD, LC-MS, NMR). Across more than a decade in both academic and industry settings — including senior roles in R&D and commercial functions — I have co-authored peer-reviewed publications and I am co-inventor on four international patent applications. In my current role at Aminoverse, I help biopharma partners translate complex enzymatic and analytical challenges into practical, decision-ready assay solutions.
Enzymatic polysorbate degradation is a recurring cause of biologics stability failure, driven by host-cell lipases and esterases that co-purify with the antibody at sub-ppm levels. Total HCP by ELISA can pass release spec while these enzymes stay active, and LC-MS names the species present without showing which are catalytically dangerous at formulation pH. This talk presents a high-throughput fluorogenic activity assay, qualified across five drug-substance matrices at pH 4.0 to 6.5, that detects and ranks active enzymes in the sub-ppm risk zone. Using a biosimilar IgG1 case study co-developed with Sandoz, we show a 33% polysorbate-80 loss that passed ELISA, resolved by inhibitor fingerprinting to identify the dominant active driver and a latent acidic-excursion risk.